Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
39 studies found for:    "Microscopic polyangiitis"
Show Display Options
Rank Status Study
21 Enrolling by invitation VCRC Patient Contact Registry Patient-Reported Data Validation Study
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Giant Cell Arteritis;   Wegener Granulomatosis;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
22 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
23 Completed Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
Conditions: ANCA Associated Systemic Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis
Intervention: Drug: cyclophosphamide
24 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
25 Completed Reproductive Health in Men and Women With Vasculitis
Conditions: Giant Cell Arteritis;   Takayasu's Arteritis;   Polyarteritis Nodosa;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Behcet's Disease;   Kawasaki Disease;   Henoch-schoenlein Purpura;   Vasculitis, Central Nervous System;   Drug-induced Necrotizing Vasculitis
Intervention:
26 Terminated Plasma Exchange for Renal Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Procedure: Plasma exchange;   Drug: Intravenous methyl prednisolone;   Drug: Methyl prednisolone
27 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone
28 Unknown  Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Conditions: Wegener's Granulomatosis;   Churg-Strauss Syndrome;   Microscopic Polyangiitis;   Polyarteritis Nodosa
Interventions: Drug: Methotrexate;   Drug: Cyclophosphamide
29 Completed Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa
Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides;   Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;   Drug: Mycophenolate mofetil,methotrexate
30 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
31 Completed Educational Needs of Patients With Systemic Vasculitis
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Vasculitis, Central Nervous System;   Giant Cell Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
32 Terminated IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Conditions: ANCA Associated Systemic Vasculitis Including Wegener’s;   Granulomatosis and Microscopic Polyangiitis and;   Renal Limited Vasculitis
Interventions: Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Azathioprine;   Drug: Prednisone (and methylprednisolone)
33 Not yet recruiting A Study Evaluating the Safety and Efficacy of Ristova (Rituximab) in Combination With Glucocorticoids in Patients With Wegener's Granulomatosis or Microscopic Polyangitis
Condition: Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions: Drug: methylprednisolone;   Drug: prednisone;   Drug: rituximab [Ristova]
34 Unknown  Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
Conditions: Wegener's Granulomatosis;   Vasculitis
Interventions: Drug: mycophenolate mofetil;   Drug: cyclophosphamide
35 Recruiting Belimumab in Remission of VASculitis
Condition: Vasculitis
Interventions: Biological: Placebo;   Biological: Belimumab 10 mg/kg;   Drug: Azathioprine
36 Terminated Intravenous Immunoglobulin After Relapse in Vasculitis
Conditions: ANCA + Vasculitides Relapsing Either Under Corticosteroid;   and Immunosuppressant Therapies or After One Year;   Post Treatment.
Intervention: Drug: Intravenous immunoglobulins (human immunoglobulins G)
37 Recruiting Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
Condition: Granulomatosis With Polyangiitis
Interventions: Other: Blood samples and clinical data;   Other: Blood sample
38 Terminated Abatacept in ANCA Associated Vasculitis
Condition: ANCA-associated Vasculitis
Intervention: Drug: Abatacept (Orencia)
39 Unknown  WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
Condition: Systemic Wegener's Granulomatosis
Interventions: Drug: Azathioprine: 2 mg/kg/day;   Drug: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page   
Indicates status has not been verified in more than two years